Brief: Seres Therapeutics Q3 EPS USD -0.37
02/11/2023 11:00
Nov 02 (Reuters) - Seres Therapeutics Q3 collaboration revenue USD 310 thousand. * Q3 operating income USD -47.413 million * Q3 net income USD -47.854 million * Q3 operating expenses USD 47.723 million
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47